CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
Palo Alto, California, United States and 45 other locations
The investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly...
Berkeley, California, United States
and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether admin ...
Phase 2
Walnut Creek, California, United States and 23 other locations
on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's...
Phase 2
San Francisco, California, United States and 34 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
San Francisco, California, United States and 109 other locations
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease...
Phase 3
Palo Alto, California, United States and 114 other locations
-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.Part A consists of a Screening Period (up t...
Phase 1
Walnut Creek, California, United States and 24 other locations
versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...
Phase 2
Palo Alto, California, United States and 102 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...
Phase 3
San Francisco, California, United States of America and 246 other locations
capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 o...
Phase 3
Walnut Creek, California, United States and 162 other locations
Clinical trials
Research sites
Resources
Legal